Trial Profile
Phase II Study of Neoadjuvant Gemcitabine, Nab-paclitaxel, Durvalumab (MEDI4736) (Anti-PD-L1), and Oleclumab (Anti-CD73) in the Treatment of Resectable/Borderline Resectable Primary Pancreatic Adenocarcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Gemcitabine (Primary) ; Oleclumab (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Oct 2023 Planned End Date changed from 30 Oct 2024 to 30 Oct 2025.
- 26 Oct 2023 Planned primary completion date changed from 30 Oct 2024 to 30 Oct 2025.
- 12 Oct 2023 Planned primary completion date changed from 30 Oct 2023 to 30 Oct 2024.